Cryptogenic StrokeNCT07126184
Incidence and Predictors of Recurrent Stroke in Cryptogenic Stroke Patients With Atrial Fibrillation
An observational study of Cryptogenic Stroke and Atrial Fibrillation, run by Nangarhar University at 1 site in Pakistan.
Trial summary
Brief Summary: This study aimed to investigate the risk and factors that predict recurrent stroke in patients who initially had a stroke with no clear cause (called cryptogenic stroke) and were later found to have atrial fibrillation (AF), an irregular heart rhythm that can increase stroke risk. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cryptogenic Stroke, Atrial Fibrillation, Recurrent Ischemic Stroke
- What is being tested?
- Extended Cardiac Monitoring
- How many people
- 109 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Jan 2018to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study includes adult patients admitted to Lady Reading Hospital with cryptogenic ischemic stroke who were later diagnosed with atrial fibrillation within 12 months. The cohort was followed for recurrent stroke and clinical outcomes over a median of 13.8 months.
Who may be able to join
- Adults aged 18 years or older.
- Patients initially diagnosed with cryptogenic ischemic stroke confirmed by neuroimaging and standard diagnostic evaluation.
- Patients subsequently diagnosed with atrial fibrillation within 12 months of index stroke, confirmed by ECG, 24-hour Holter monitoring, or implantable loop recorder.
- Availability of complete clinical and follow-up data.
Who cannot join
- Known history of atrial fibrillation or atrial flutter prior to the index stroke.
- Presence of structural heart diseases, valvular abnormalities, or congenital cardiac anomalies.
- Incomplete clinical or follow-up data.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Incidence and Predictors of Recurrent Stroke in Patients With Cryptogenic Stroke Later Diagnosed With Atrial Fibrillation: A 5-Year Study From Lady Reading Hospital, Peshawar
Brief Summary:
This study aimed to investigate the risk and factors that predict recurrent stroke in patients who initially had a stroke with no clear cause (called cryptogenic stroke) and were later found to have atrial fibrillation (AF), an irregular heart rhythm that can increase stroke risk. The study was conducted at Lady Reading Hospital in Peshawar, Pakistan, over five years from 2018 to 2023.
Read more
Stroke is a leading cause of death and disability worldwide. In many cases, the cause of stroke is unclear, which makes it difficult to prevent it from happening again. Atrial fibrillation is a common hidden cause of such strokes but is often hard to detect because it can occur intermittently without symptoms. Detecting AF early is important because patients with AF benefit greatly from blood-thinning medicines (anticoagulants) that reduce the risk of another stroke.
In this study, medical records of patients diagnosed with cryptogenic stroke were reviewed. Patients who were later diagnosed with atrial fibrillation within 12 months of their stroke were included. The researchers collected information about their age, gender, heart examinations, how and when AF was diagnosed, use of blood-thinning medicines, and if they had another stroke during follow-up.
The study highlights the importance of early and prolonged heart rhythm monitoring in patients with cryptogenic stroke to detect atrial fibrillation. It also stresses the need for better access to and adherence to anticoagulant therapy in resource-limited settings like Pakistan to reduce the risk of recurrent stroke and improve patient outcomes.
- Being tested
- Extended Cardiac Monitoring
- Keywords
- Cryptogenic stroke, Atrial Fibrillation, Recurrent Ischemic Stroke, Ischemic stroke
- Medical subject headings
- Ischemic Stroke, Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Extended Cardiac MonitoringDiagnostic test
This observational study involved the use of standard cardiac monitoring methods to detect atrial fibrillation in patients initially diagnosed with cryptogenic ischemic stroke. Monitoring techniques included 12-lead ECG, 24-hour Holter monitoring, and implantable loop recorders (ILRs). No experimental interventions were assigned; patients received routine clinical care.
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Recurrent Ischemic Stroke
Occurrence of new ischemic stroke confirmed by clinical assessment and neuroimaging during the follow-up period in patients initially diagnosed with cryptogenic stroke and later diagnosed with atrial fibrillation.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2025
- Study start1 Jan 2018
- Primary completion14 Dec 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cryptogenic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 109 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nangarhar University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rafiullah Hotak, Nangarhar University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07126184
- Sponsor's protocol ID
- Ref: No. 331/LRH/MTI
- Status last verified
- Aug 2025
- First submitted
- 10 Aug 2025
- Last updated
- 17 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Incidence and Predictors of Recurrent Stroke in Patients With Cryptogenic Stroke Later Diagnosed With Atrial Fibrillation: A 5-Year Study From Lady Reading Hospital, Peshawar
- ClinicalTrials.gov ID
- NCT07126184
- Acronym / sponsor ID
- Ref: No. 331/LRH/MTI
- Keywords
- Cryptogenic stroke, Atrial Fibrillation, Recurrent Ischemic Stroke, Ischemic stroke
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 109 participants (actual)
- Lead sponsor
- Nangarhar UniversityUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 14 Dec 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 17 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Brief Summary:
This study aimed to investigate the risk and factors that predict recurrent stroke in patients who initially had a stroke with no clear cause (called cryptogenic stroke) and were later found to have atrial fibrillation (AF), an irregular heart rhythm that can increase stroke risk. The study was conducted at Lady Reading Hospital in Peshawar, Pakistan, over five years from 2018 to 2023.
Stroke is a leading cause of death and disability worldwide. In many cases, the cause of stroke is unclear, which makes it difficult to prevent it from happening again. Atrial fibrillation is a common hidden cause of such strokes but is often hard to detect because it can occur intermittently without symptoms. Detecting AF early is important because patients with AF benefit greatly from blood-thinning medicines (anticoagulants) that reduce the risk of another stroke.
In this study, medical records of patients diagnosed with cryptogenic stroke were reviewed. Patients who were later diagnosed with atrial fibrillation within 12 months of their stroke were included. The researchers collected information about their age, gender, heart examinations, how and when AF was diagnosed, use of blood-thinning medicines, and if they had another stroke during follow-up.
The study highlights the importance of early and prolonged heart rhythm monitoring in patients with cryptogenic stroke to detect atrial fibrillation. It also stresses the need for better access to and adherence to anticoagulant therapy in resource-limited settings like Pakistan to reduce the risk of recurrent stroke and improve patient outcomes.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study includes adult patients admitted to Lady Reading Hospital with cryptogenic ischemic stroke who were later diagnosed with atrial fibrillation within 12 months. The cohort was followed for recurrent stroke and clinical outcomes over a median of 13.8 months.
Key inclusion criteria (4 listed)
- Adults aged 18 years or older.
- Patients initially diagnosed with cryptogenic ischemic stroke confirmed by neuroimaging and standard diagnostic evaluation.
- Patients subsequently diagnosed with atrial fibrillation within 12 months of index stroke, confirmed by ECG, 24-hour Holter monitoring, or implantable loop recorder.
- Availability of complete clinical and follow-up data.
Key exclusion criteria (3 listed)
- Known history of atrial fibrillation or atrial flutter prior to the index stroke.
- Presence of structural heart diseases, valvular abnormalities, or congenital cardiac anomalies.
- Incomplete clinical or follow-up data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Extended Cardiac MonitoringThis observational study involved the use of standard cardiac monitoring methods to detect atrial fibrillation in patients initially diagnosed with cryptogenic ischemic stroke. Monitoring techniques included 12-lead ECG, 24-hour Holter monitoring, and implantable loop recorders (ILRs). No experimental interventions were assigned; patients received routine clinical care. | Diagnostic test | – |
Primary outcome
Incidence of Recurrent Ischemic Stroke
Time frame: 5 years
Occurrence of new ischemic stroke confirmed by clinical assessment and neuroimaging during the follow-up period in patients initially diagnosed with cryptogenic stroke and later diagnosed with atrial fibrillation.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Cryptogenic Stroke
Recruiting
Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke
Patent Foramen Ovale, Ischemic Stroke
Not yet recruiting
CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
Atrial Fibrillation (AF)
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 4
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
Stroke, Stroke, Acute Ischemic
Recruiting
Intensive Cancer Screening After Cryptogenic Stroke
Occult Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cryptogenic Stroke and Atrial Fibrillation, run by Nangarhar University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Recurrent Ischemic Stroke (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2025.